PH12015500689A1 - Azaquinazoline inhibitors of atypical protein kinase c - Google Patents

Azaquinazoline inhibitors of atypical protein kinase c

Info

Publication number
PH12015500689A1
PH12015500689A1 PH12015500689A PH12015500689A PH12015500689A1 PH 12015500689 A1 PH12015500689 A1 PH 12015500689A1 PH 12015500689 A PH12015500689 A PH 12015500689A PH 12015500689 A PH12015500689 A PH 12015500689A PH 12015500689 A1 PH12015500689 A1 PH 12015500689A1
Authority
PH
Philippines
Prior art keywords
azaquinazoline
inhibitors
protein kinase
atypical protein
atypical
Prior art date
Application number
PH12015500689A
Other versions
PH12015500689B1 (en
Inventor
Henry J Breslin
Bruce D Dorsey
Benjamin J Dugan
Katherine M Fowler
Robert L Hudkins
Eugen F Mesaros
Monck Nathaniel Jt
Emma L Morris
Olowoye Ikeoluwa
Gregory R Ott
Gregoire A Pave
Jonathan R A Roffey
Christelle N Soudy
Tao Ming
Craig A Zificsak
Allison L Zulli
Original Assignee
Ignyta Inc
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc, Cancer Rec Tech Ltd filed Critical Ignyta Inc
Publication of PH12015500689B1 publication Critical patent/PH12015500689B1/en
Publication of PH12015500689A1 publication Critical patent/PH12015500689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Abstract

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
PH12015500689A 2012-09-28 2015-03-26 Azaquinazoline inhibitors of atypical protein kinase c PH12015500689A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707340P 2012-09-28 2012-09-28
US201361781364P 2013-03-14 2013-03-14
PCT/US2013/062085 WO2014052699A1 (en) 2012-09-28 2013-09-27 Azaquinazoline inhibitors of atypical protein kinase c

Publications (2)

Publication Number Publication Date
PH12015500689B1 PH12015500689B1 (en) 2015-05-25
PH12015500689A1 true PH12015500689A1 (en) 2015-05-25

Family

ID=49326872

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015500689A PH12015500689A1 (en) 2012-09-28 2015-03-26 Azaquinazoline inhibitors of atypical protein kinase c

Country Status (19)

Country Link
US (2) US9914730B2 (en)
EP (1) EP2900666B1 (en)
JP (1) JP6535430B2 (en)
KR (1) KR102215272B1 (en)
CN (1) CN105102456B (en)
AU (1) AU2013323360B2 (en)
BR (1) BR112015007061B1 (en)
CA (1) CA2886495C (en)
CL (1) CL2015000781A1 (en)
EA (1) EA030253B1 (en)
HK (2) HK1211928A1 (en)
IL (1) IL237918B (en)
MX (1) MX2015004016A (en)
NZ (1) NZ706857A (en)
PH (1) PH12015500689A1 (en)
SG (1) SG11201502301YA (en)
TW (1) TWI663165B (en)
WO (1) WO2014052699A1 (en)
ZA (1) ZA201502783B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030253B1 (en) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Azaquinazoline inhibitors of atypical protein kinase c
CA2895129C (en) 2012-12-20 2022-07-05 Sanford-Burnham Medical Research Institute Quinazoline neurotensin receptor 1 agonists and uses thereof
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
KR102339228B1 (en) 2013-08-23 2021-12-13 뉴파마, 인크. Certain chemical entities, compositions, and methods
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
TWI675836B (en) * 2014-03-25 2019-11-01 美商伊格尼塔公司 Azaquinazoline inhibitors of atypical protein kinase c
WO2015200534A2 (en) * 2014-06-25 2015-12-30 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2015311730A1 (en) * 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
KR102510588B1 (en) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic inhibitors of cathepsin c
WO2016068580A2 (en) * 2014-10-29 2016-05-06 Dong-A Socio Holdings Co., Ltd. Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CN105288512A (en) * 2015-12-08 2016-02-03 李野林 Traditional Chinese medicine composition for treating obesity
MA45244A (en) 2016-06-13 2019-04-17 Cancer Research Tech Ltd SUBSTITUTED PYRIDINES USED AS DNMT1 INHIBITORS
CN109843858B (en) * 2016-08-15 2023-05-05 润新生物公司 Certain chemical entities, compositions and methods
JP6954994B2 (en) * 2016-08-16 2021-10-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Oxo-imidazolepyridine as a reversible BTK inhibitor and its use
JOP20190257A1 (en) * 2017-04-28 2019-10-28 Novartis Ag 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
JP7039802B2 (en) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Pharmaceutical composition containing RHO-related protein kinase inhibitor, RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition.
CN110573501B (en) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
CN117343049A (en) 2017-06-30 2024-01-05 北京泰德制药股份有限公司 Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
DK3827005T3 (en) * 2018-07-25 2022-09-19 Faes Farma Sa Pyridopyrimidines as histamine H4 receptor inhibitors
US20210347785A1 (en) * 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
CN111100063B (en) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 Preparation method for synthesizing 2-fluoromethyl substituted pyrrolidine, piperidine and piperazine derivatives
KR20220002930A (en) * 2019-03-28 2022-01-07 캔써 리서치 테크놀로지 리미티드 Inhibitors of atypical protein kinase C and their use in the treatment of hedgehog pathway dependent cancers
CN114349711B (en) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (en) 1972-08-16 1974-04-05
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002080423A (en) * 2000-09-06 2002-03-19 Daikin Ind Ltd Method for synthesizing ethyl trifluoroacetate
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
FR2846657B1 (en) 2002-11-05 2004-12-24 Servier Lab NOVEL PYRIDOPYRIMIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2004092196A2 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1871377A1 (en) * 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
ES2648388T3 (en) * 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivatives of 2-methylmorpholin pyrido-, pyrazo- and pyrimido-pyrimidine as mTOR inhibitors
BRPI0716880A2 (en) * 2006-09-08 2013-10-15 Pfizer Prod Inc SYNTHESIS OF 2- (PYRIDIN-2-YLAMINO) -PYRID [2,3-D] PYRIMIDIN-7-ONAS
CN102984941B (en) * 2009-09-04 2016-08-17 密执安大学评议会 For treating leukemic compositions and method
EA030253B1 (en) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Azaquinazoline inhibitors of atypical protein kinase c
CA2904612A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) * 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US20190010167A1 (en) * 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Also Published As

Publication number Publication date
WO2014052699A1 (en) 2014-04-03
US9914730B2 (en) 2018-03-13
HK1211928A1 (en) 2016-06-03
AU2013323360B2 (en) 2017-09-07
NZ706857A (en) 2018-05-25
WO2014052699A9 (en) 2015-07-16
CN105102456B (en) 2017-11-14
EA201590661A1 (en) 2015-09-30
KR102215272B1 (en) 2021-02-15
TWI663165B (en) 2019-06-21
CL2015000781A1 (en) 2016-04-01
PH12015500689B1 (en) 2015-05-25
BR112015007061A8 (en) 2019-08-20
IL237918A0 (en) 2015-05-31
JP2015533822A (en) 2015-11-26
KR20150086248A (en) 2015-07-27
EP2900666B1 (en) 2020-11-04
AU2013323360A1 (en) 2015-04-30
US9896446B2 (en) 2018-02-20
CN105102456A (en) 2015-11-25
BR112015007061A2 (en) 2017-07-04
ZA201502783B (en) 2016-01-27
US20140113882A1 (en) 2014-04-24
CA2886495C (en) 2023-09-19
MX2015004016A (en) 2016-02-18
JP6535430B2 (en) 2019-06-26
CA2886495A1 (en) 2014-04-03
BR112015007061B1 (en) 2022-10-04
EA030253B1 (en) 2018-07-31
TW201427978A (en) 2014-07-16
US20160102094A1 (en) 2016-04-14
HK1212336A1 (en) 2016-06-10
IL237918B (en) 2021-05-31
EP2900666A1 (en) 2015-08-05
SG11201502301YA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
MX355088B (en) Thienopyrimidine inhibitors of atypical protein kinase c.
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017502141A1 (en) Compounds and their methods of use
EA201391390A1 (en) CYCLOPROPYLAMINES AS LSD INHIBITORS
MX2018000396A (en) Substituted aza compounds as irak-4 inhibitors.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
TW201613945A (en) Compounds and compositions as kinase inhibitors
PH12014502513A1 (en) Nampt inhibitors
MD20150071A2 (en) Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of CNS and other disorders
MX2014013752A (en) Nampt inhibitors.
PH12016501462A1 (en) Neprilysin inhibitors
EA201590552A1 (en) AMINOHINOLINES AS KINASE INHIBITORS
EA201590744A1 (en) TORRING OF TOR CANCER BY KINASE INHIBITORS
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
UA109932C2 (en) CYCLOPROPYLAMINS AS LSD1 INHIBITORS
MX2015009678A (en) 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors.